CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 97 enrolled
Drug / intervention
Buprenorphine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03150173
NCT03150173Phase 2Completed
CompareCT.gov

Buprenorphine Treatment at Syringe Exchanges to Reduce Opioid Misuse and HIV Risk

Montefiore Medical Center·interventional·Posted May 12, 2017·Updated Dec 11, 2025

In Brief

A Phase 2 clinical trial evaluating Onsite treatment, Enhanced referral, and 1 other intervention for Opiate Addiction. Completed, enrolled 97 participants across 3 sites.

Detailed Summary

This trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community health center for buprenorphine treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpiate Addiction
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 12, 2017
Enrollment StartJan 2, 2019
Primary CompletionOct 11, 2023
Study CompletionMar 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.1 years ago

Interventions

Onsite treatmentbehavioral

Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.

Enhanced referralbehavioral

Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment

Buprenorphinedrug

all participants will receive buprenorphine